| name | ata-ppgl-imaging-modality-selection |
| description | Selects the initial imaging modality (CT, MRI, 123I-MIBG scintigraphy, or 18F-FDG PET) for suspected pheochromocytoma and paraganglioma based on clinical question (tumor localization vs metastasis detection) and patient factors. Triggered by biochemical confirmation of PPGL or strong clinical suspicion when clinicians ask 'What imaging test should I order for suspected pheochromocytoma?' |
Select initial imaging modality for suspected pheochromocytoma and paraganglioma
STEP 1 — Gather Information
Collect biochemical confirmation (fractionated metanephrines or plasma-free metanephrines >3× upper limit of normal), assess clinical suspicion, patient factors (age, pregnancy, renal function, need for radiation avoidance), clinical question (localize primary tumor vs detect metastasis), and known genetic status (especially SDHx variants).
STEP 2 — Rule In / Rule Out
Is the primary clinical question tumor localization (identifying the primary lesion and its anatomic relationships) or metastasis detection? If localization → proceed to Step 3 for localization; if metastasis detection → proceed to Step 3 for metastasis.
STEP 3 — Classify or Stratify
For localization: Choose MRI if patient is a child, pregnant, requires frequent follow‑up imaging, or to avoid radiation; otherwise choose contrast‑enhanced CT for superior spatial resolution, especially when lung or liver involvement is suspected.
For metastasis detection: If SDHx pathogenic variant is known or suspected, order 18F‑FDG PET; otherwise order 123I‑MIBG scintigraphy with thyroid blockade (potassium iodide 50–150 mg/day or Lugol’s solution 5–10 drops/day starting 3 days prior).
STEP 4 — Decide
Order the selected imaging modality and schedule thyroid blockade if 123I‑MIBG scintigraphy is chosen.
Clinical Guardrails / Mimics / Pitfalls
Avoid CT in children or pregnant patients when MRI suffices; do not rely on 123I‑MIBG alone in SDHx‑related PPGL due to false negatives; remember thyroid blockade to prevent thyroid uptake and medullary thyroid cancer interference; 18F‑FDG PET is less specific for primary tumor characterization; ensure biochemical confirmation precedes imaging to reduce false‑positive work‑ups.
Concrete Clinical Example
A 45‑year‑old woman with paroxysmal hypertension and headaches has plasma‑free metanephrines 4× ULN. She is non‑pregnant and requires anatomic detail of a right adrenal mass. Clinical question is localization. She opts for contrast‑enhanced CT of the abdomen/pelvis after confirming biochemical PPGL.
Source: Japan Endocrine Society Clinical Practice Guideline for the Diagnosis and Management of Pheochromocytoma and Paraganglioma 2025, Japan Endocrine Society, 2025, doi:10.1507/endocrj.EJ25-0165
